Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome

Circulation. 1977 Jan;55(1):15-22. doi: 10.1161/01.cir.55.1.15.

Abstract

Thirty-three patients with Wolff-Parkinson-White syndrome were studied electrophysiologically before and after administration of intravenous procainamide and oral quinidine sulfate. Procainamide prolonged the shortest R-R (SRR) interval between two consecutive pre-excited beats during atrial fibrillation 20-70 msec in 15 of 21 patients with no change observed in 6 of 21 patients. Quinidine sulfate prolonged the SRR 20-170 msec in all 16. In 14 of 18 patients where procainamide and quinidine were comparable, quinidine prolonged the SRR 30-100 msec more than procainamide.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / physiopathology
  • Electrophysiology
  • Female
  • Humans
  • Male
  • Procainamide / pharmacology*
  • Procainamide / therapeutic use
  • Quinidine / pharmacology*
  • Quinidine / therapeutic use
  • Wolff-Parkinson-White Syndrome / drug therapy
  • Wolff-Parkinson-White Syndrome / physiopathology*

Substances

  • Quinidine
  • Procainamide